<DOC>
	<DOCNO>NCT01745055</DOCNO>
	<brief_summary>This study design estimate effect methotrexate ( MTX ) pharmacokinetics ( PK ) CP-690,550 administered subject rheumatoid arthritis ( RA ) , estimate effect CP-690,550 PK MTX evaluate short-term safety tolerability co-administration CP-690,550 MTX .</brief_summary>
	<brief_title>Co-Administration Of Methotrexate And CP-690,550</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Adults diagnose moderate severe RA ( Rheumatoid Arthritis ) Diagnosis RA base American College Rheumatology 1987 revise criterion . Treatment oral stable weekly dose Methotrexate ( MTX ) ( 1525 mg/week , administer single dose [ SD ] ) minimum 4 dos ( 4 week ) Blood dyscrasia include confirm : Hemoglobin &lt; 9 g/dL Hematocrit &lt; 30 % ; White blood cell count &lt; 3.0 x 109/L ; Absolute neutrophil count &lt; 1.2 x 109/L ; Platelet count &lt; 100 x 109/L Evidence history clinically significant infection within past 6 month ( eg , require hospitalization , require parenteral antimicrobial therapy , recurrent oral genital herpes , recurrent herpes zoster , infection otherwise judge investigator potential exacerbation participation trial . Total bilirubin , AST ( aspartate aminotransferase ) ALT ( alanine aminotransferase ) 1.2 time upper limit normal Screening visit , history clinically significant elevate liver function test ( LFTs ) current MTX dose chronic liver disease , recent active hepatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>oral JAK inhibitor</keyword>
	<keyword>methotrexate ( MTX )</keyword>
	<keyword>rheumatoid arthritis ( RA )</keyword>
</DOC>